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mfections, including Streptococcus pneumoniae, and the management of 
these infections with those agents has become a distinct possibility. 
I S143 1 Quinolones in Nosocomial Respiratory Tract 
Infections 
H. Lode. Department of Chest and Infertiow Diseases, Hospital 
HeckeshowdZehlendorj Free University Berlin, Berlin, Germany 
The newer quinolones have excellent in vitro activity against most 
of the important respiratory pathogens, such as Haemophilus in- 
juenzae, Mormella catanhalis, Staphylococcus aurarr, including m e h -  
ciUin-resistant strains,  and Enterobacteriaceae. In addition, the res- 
piratory intracellular pathogens, Legionelfa species, Mycoplasma pneu- 
moniae, Chlamydia pneumoniae, Mycobacferium tuberculosis, and Mycobac- 
terium avium-intrace~lulare, are inhibited to variable degrees, depending 
upon the strain used and the quinolone tested. 
Concerning the pharmacohnetics of newer quinolones, they usu- 
ally achieve excellent concentrations in bronchial tissue, sputum, 
alveolar lining fluid, and in alveolar macrophages, with concentra- 
tions in many cases five to ten times higher than the concomitant 
serum concentrations. 
Several recent clinical studies have demonstrated that modern 
quinolones are as active as other recently developed antibiotics, 
such as carbapenems, third- and fourth-generation cephalosporins, 
broad-spectrum p e n i d h  together with p-lactamase inhibitors, and 
combination treatments of Merent antibiotics. Initial selection of an 
antibiotic for the treatment of hospital-acquired pneumonia relies 
on assessments of disease severity, the presence of risk factors for 
specific organisms, and the time of onset of the lower respiratory 
tract infection. In a recent American Thoracic Society statement, 
quinolones occupy a leadmg place in the treatment of severe hos- 
pital-acquired pneumonia with risk factors and early onset, and in 
patients with severe hospital-acquired pneumonia with late onset. 
However, for infections induced by hlghly resistant strains, such as 
Pseudomonas aeruginosa, Acinetobacter species, and Stenotrophomonas, the 
optimal combination partner for quinolones is not yet defined. 
I S144 I The Use of Quinolones in Novel Therapeutic 
Areas 
J.-C. Pechsre. Depament  of Geneticr and Microbiology, Univmity  of 
Geneva, Genm, Switzerland 
The first quinolone antibiotics were only suitable for treating urinary 
and some gastrointestinal infections, because their activity was re- 
stricted to Gram-negative organisms, most notably the Enterobacte- 
riaceae. The last 30 years have seen the expansion of the quinolones’ 
spectra of activity. Currently adable  fluoroquinolones possess some 
activity against Gram-positive cocci, while sd displaying good ac- 
tivity against Gram-negative organisms. These agents are, however, 
s t i l l  not noted for their activity against anaerobes, and activity against 
atypical pathogens is suboptimal, thus restricting their uses against 
these organism. 
Quinolones’ pharmacokinetic properties have also evolved, al- 
though bioavailabhty remains far h m  perfect: protein binding of 
many agents is high; tissue penetration is less than ideal; and tissue 
half-lives are short. As a consequence, the fluoroquinolones cur- 
rently in use usually have to be administered more than once daily 
to achieve good clinical efficacy. 
The development of new fluoroquinolones, such as trodoxacin, 
that possess enhanced activity against pneumococci and atypical 
pathogens, means the availability of single-agent therapy for the em- 
piric treatment of moderate to severe respiratory tract infections, 
including nosocomial pneumonia. Good pneumococcal activity also 
points to the use of trodoxacin for the meatment of meningitis in 
children, especially now that concerns about arthropathy have been 
proved unfounded following experience of prolonged use of fluoro- 
quinolones in cystic fibrosis patients. Expansion of the spectrum of 
activity to include anaerobes, as well as enterobacteria, also results, 
for the first t h e ,  in a quinolone that can be confidently used for the 
treatment of intra-abdominal and pelvic infections, and in surgical 
prophylaxis. In addition, improvement of the pharmacokinetic fea- 
tures, with enhanced tissue penetration and extended tissue half-life, 
provides the added advantage of once-daily dosing. 
I S145 1 Quinolones in the Management of Sexually 
EJ. Perea. Department of Microbiology, University of Seville, Sm’lle, 
Spain 
Early-developed fluoroquinolones are only effective against gono- 
coccus, but ciprofloxacin and especially ofloxacin have broader ac- 
tivities and are also indicated for Chlamydia trachomatis, Haemophilus 
ducreyi and Mycoplasma homonis infections, and syndromes of mixed 
etiology. Also, sparffoxacin has recently been proved effective in 
treating non-gonococcal urethritis, but its phototoxicity limits its 
use. 
Many new fluoroquinolones possess in vitro activity against geni- 
tal pathogens. Trodoxacin (CP-99,219) is a new fluoroquinolone 
with excellent activity against Neisseriagonorrhoeae and is at least three 
to four times more active than other fluoroquinolones against strains 
exhibiting decreased susceptibility to ciprofloxacin. Preliminary din- 
ical stumes suggest that trodoxacin is effective in uncomplicated 
gonorrhea at a single oral dose as low as 50 mg, as well as having 
in vitro activity against C. trachomatis. At doses as low as 200 mg/day 
given for 5 days, mvailoxacin is well tolerated and effective against 
C. trachomatis infections in both men and women, and doses of 100 
and 50 mg once daily are now being evaluated 
Chical cure rates for PID appear satisfactory using ciprofloxacin 
and ofloxacin, but they lack comprehensive in vitro coverage against 
all bacterial species implicated in PID. New Centers for Disease 
Control guidelines for outpatient treatment of PID suggest that 
ofloxacin be used alongside either dindamycin or metronidazole, 
in order to provide anaerobic coverage. 
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I S146 I Current Taxonomy and Identification of 
Anaerobic Gram-negative Bacteria 
H. Jousimies Somer. National Public Health Institute (KTL), Helsinki, 
Finland 
As a result of polyphasic taxonomic approach including 16s rRNA 
sequencing, major reorganizations among anaerobic taxa are under- 
way The gram-negative pigmented Revotella now include 7 species, 
latest inclusions being Prnigrescem (formerly part of Printermedia) and 
Fk fannerae. The non-pigmented former Mitsuokella dentalis and Hal- 
lella seregem were renamed as one species, Preuotella dentalis. Prhepari- 
nofytica and Przoogleoformans cluster withn the B$agaZis-group, but 
B.distasonis with Bforsythus among Porphyromonas. The genus Porphy- 
romonas currently includes 11 pigmented and one non-pigmented 
species; Pmtoniae (former Oribaculum catoniae). Several groups are 
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awaiting for inclusion in the genus. Furobacterium nucleaturn has 5 sub- 
species and Ewrium includes E p s e u d o n e m p h m .  The bile-sensitive 
former Bgrm'lis now are Campylobacter gradis; the bile-resistance 
ones belong to a new genus Sutterelle as S.wadnuorthiensis. 
Identification of gram-negative anaerobes beyond group level as 
obtained by rapid testing is rarely indicated, unless the case is un- 
usual, complicated and the culture result is likely to affect the ther- 
apy. Accurate species identification traditionally requires a battery of 
biochemical tests and metabolic end product or cellular fatty acid 
analysis by GLC. A rapid, less expensive but yet potential approach 
is the detection of performed enzymes. Heavy inoculum and short 
(4 h) incubation in air minimizes contamination and provides rapid 
results. Tablet or spot enzyme subtrates allow tailoring of identifi- 
cation sets at low cost. For accurate identification of anaerobes and 
for taxonomic purposes, reference laboratories find cellular fatty acid 
profiling, 16s rRNA sequencing and DNA probes valuable. 
Sacternides fragiis Polysaccharides Mediate 
lntraabdominal Abscess Formation 
D.L. Kasper, A.O. Tzianabos. Channing hboratory, Brigham and 
Women? Hospital, Harvard Medical School, Boston, MA, USA 
Bacteroides hgilis is one of the bacterial species which has the 
propensity to induce abscesses which are one of the characteristic 
host pathological responses to infection. The B. J?agilis component 
responsible for abscess induction is a unique capsular polysaccharide 
complex comprising two hstinct polysaccharides, PS A and PS B. 
In animal models, PS A is more potent than PS B in inducing ab- 
scesses when implanted directly into the peritoneum. Each repeating 
unit of PS A has one positively charged group (a h e  amino residue) 
and one negatively charged group (pyruvate). Chemical techniques 
were used to neutrahe the charge on either of these residues and 
resulted in polysaccharides that were not able to induce abscesses. 
Another unique biologic attribute of PS A is its abihty to prevent 
the development of inmaabdominal abscesses caused by B. jagilis and 
by other unrelated bacteria capable of inducing abscesses. Kinetic 
studies demonstrated that PS A was protective against abscesses even 
when given 4 hours after intraperitoneal bacterial challenge. Im- 
munologic studies indicated that CD4+ T cells were able to transfer 
to naive rats protection against abscesses. In vitro studies demon- 
strated potent mitogenic stimulation by PS A on nonimmune CD4+ 
T cells in the presence of feeder cells. Charge neutralization of PS A 
eliminates its mitogenic capacity. PS A has many biological propemes 
that are unusual for polysaccharides that are related to the distinctive 
structural attributes of t h i s  molecule. 
Anaerobic Bacteria in Respiratory Tract 
Infections 
C.E. Nord. Huddinge Uniwrsity Hospital, kizrolinska Institute, 
Stockholm, Sweden 
The anaerobic bacteria which predominate in respiratory tract infec- 
tions are Bacferoides Jagilis group, Prevotella, Porphyromonas, Fusobac- 
terium and Peptosfreptococrur species. These bacteria have one or more 
virulence factors including the adhesion to epithelial surfaces, the 
invasion of cell tissues, the production of toxins/enzymes and the 
cell surfaces constituents. Most anaerobic bacteria involved in res- 
piratory tract infections were susceptible to the antimicrobial agents 
used until a few years ago. Resistance to different agents such as 
beta-kctam antibiotics, clindamycin and memnidazole has been de- 
scribed during the last years. Resistance is of major importance in 
the B. jagilis group. While other groups of anaerobic bacteria have 
remained substantally stable in their susceptibility patterns, the Bac- 
teroides group and Prevotella, Porphyromonas and Fusobactm'um species 
have become increasingly resistant to many anti-anaerobic agents as 
their use have become more widespread. Antimicrobial therapy of 
anaerobic infections must be prolonged to avoid relapses, because of 
the marked tendency for anaerobes to cause tissue necrosis, abscess 
formation and septic thrombophlebitis. Drugs commonly used in the 
treatment of anaerobic respiratory tract infections are beta-lactam an- 
tibiotics, clindamycin, metronidamle and beta-lactam compounds in 
combination with beta-lactamase inhibitors. 
F] Anaerobic Bacteria in lntraabdominal Infections 
H. Giamarellou. Athens University School OfMediCine, Athens, Greece 
The majority of IAI are secondary to contamination of the peri- 
toneal cavity with enteric organisms after injury to the gastroin- 
testinal tract or as sequelae of pathologic processes leading to organ 
ischemia. Therefore MI are endogenous derived from the microbial 
flora of the gastrointestinal tract which is the most complex microbial 
ecosystem of the manunah ' body with up to lo'* viable bacteria 
per gram of gut content, and up to 400-500 different species. Newly 
described species like Bilofila wadsworba, is implicated in -50% 
of patients with gangrenous and perforated appendicitis. B. f m g h  
however still represents the most commonly encountered species. Its 
specific virulence factors providing an explation for its unique im- 
plication in IAI include: (I) The capsule that protects against phago- 
cytosis, 01) the fimbriae that attach directly to peritoneal mesothelial 
cells, (III) the production of heparinase and chondroitin sulfatase. 
The most important factor in the treatment of inmaabdominal infec- 
tions are early diagnosis and prompt surgical intervention while an- 
tibiotic play a secondary role. Antianaerobic agents include chloram- 
phenicol, dindamycin and the nimimidazoles while the inhibitors, 
cefoxitin, cefotetan, ceftizoxime, carbapenems and some advanced 
quinolones like mvafloxacin represent single drugs to cover both 
aerobic gram negatives and anaerobic microflora. Although that al- 
most all climcal trials usually end up with >900/0 efficacy rate, the 
final outcome is dependant on the stage of the mfection (early versus 
late), sepsis score, underlying diseases and the applied surgical proce- 
dures. The choice of antibiotic@) must be influenced by its toxicity, 
local nosocomial susceptibility patterns, resistance inducing abihty 
and the cost. 
(IAl) 
Perspectives in the management of 
opportunistic infections in HIV infected 
patients 
I S150 I G-CSF, an Anti-inflammatory Cytokine: Its 
Potential Role in Infectious Disease 
T. Hartung, H.-D. Volk, A. Wendel. Uniuersify OfKonstanz, Germany 
In three double-blind placebo conmlled studies, a total of 56 healthy 
volunteers were treated S.C. with G-CSF (NeupogenR). G-CSF 
treatment raised blood neutrophil (PMN) counts lOfold and primed 
PMN functions such as oxidative burst, bactericidal killing as well 
as release of interleukin-1 receptor antagonist and soluble TNF re- 
ceptors. However, degranulation was d e c t e d  and the release of 
the chemokme leukomene B4 was even attenuated. Thus, G-CSF is 
not a mere PMN activator but Meentially regulates Merent PMN 
functions. 
In addition, single injection of G-CSF resulted also in a a-ansient 
2-3 fold monocytosis. When whole blood of G-CSF treated donors 
